DAFTAR PUSTAKA

1. Huang C, Wang Y, Li X, et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet*. 2020; 395: 497-506.

2. Nishiura H, Sung-mok J, Linton N, et al. Extent of Transmission of Novel Coronavirus in Wuhan, China, 2020. *Journal of Clinical Medicine*. 2020; 330: 1-5.

3. Xu T, Chen C, Zhu Z, et al. Clinical Features and Dynamics of Viral Load in Imported and Non-Imported Patients with COVID-19. *International Journal of Infectious Diseases*. 2020; 94: 68-71.

4. Li T, Wang L, Wang H, et al. Characteristics of Laboratory Indexes in COVID-19 Patients with Non-Severe Symptoms in Hefei City, China: Diagnostic Value in Organ Injuries. *European Journal of Clinical Microbiology & Infectious Diseases*. 2020; 39(12): 2447-55.

5. Burhan E, Isbaniah F, Susanto AD, et al. Pendahuluan. Diagnosis dan Penatalaksanaan Pneumonia COVID-19 di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia. 2020: 1-3.

6. Sitorus RJ, Wathan I, Ridwan H, et al. Transmission Dynamics of Novel Coronavirus – SARS-CoV-2 in South Sumatera, Indonesia. *Clinical Epidemiology and Global Health*. 2021; 11: 1-4.

7. Huang Y, Chen S, Yang Z, et al. SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients. *American Journal of Respiratory and Critical Care Medicine*. 2020; 201(11): 1435-38.

8. Augustin M, Schommers P, Stecher M, et al. Post-COVID Syndrome in Non-Hospitalised Patients with COVID-19 : A Longitudinal Prospective Cohort Study. *Lancet*. 2021; 6: 1-8.

9. Chen W, Lan Y, Yuan X, et al. Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity. *Emerging Microbes & Infections*. 2020; 9(1): 469-73.

10. Wang C, Wang Z, Wang G, et al. COVID-19 in Early 2021: Current Status and Looking Forward. *Signal Transduction and Targeted Therapy*. 2021; 6: 1-14.

11. Kementerian Kesehatan Republik Indonesia. Pendahuluan. Pedoman Pencegahan dan Pengendalian *Corona Virus Disease* (COVID-19) Revisi Ke-5. *Kementerian Kesehatan RI*. 2020; 5: 17-24.

12.	Gugus Tugas Percepatan Penanganan COVID-19. Data Sebaran Situasi Virus COVID-19 di Indonesia. Accesed in April 2021. Available at: https://covid19.go.id.

13.	Sulsel Tanggap COVID-19. Accesed in April 2021. Available at: https://covid19.sulselprov.go.id/.

14.	Karahasan YA, Sarinoglu RC, Bilgin H, et al. Relationship of The Cycle Threshold Values of SARS-CoV-2 Polymerase Chain Reaction and Total Severity Score of Computerized Tomography in Patients with COVID 19. *International Journal of Infectious Diseases*. 2020; 101: 160-6.

15.	Kam KQ, Yung CF, Cui L, et al. A well infant with coronavirus disease 2019 with high viral load. *Clinical Infectious Diseases*. 2020; 71(15):847-9.

16.	Yu X, Sun S, Shi Y, et al. SARS-CoV-2 Viral Load in Sputum Correlates with Risk of COVID-19 Progression. *Critical Care*. 2020;24(1):1-4.

17.	Liu Y, Yan LM, Wan L, et al. Viral Dynamics in Mild and Severe Cases of COVID-19. *Lancet*. 2020; 20(6): 656-7.

18.	Zheng S, Fan J, Yu F, et al. Viral Load Dynamics and Disease Severity in Patients Infected with SARS-CoV-2 in Zhejiang Province, China, January-March 2020: Retrospective cohort study. *British Medical Journal*. 2020; 369:1-8.

19.	Shah S, Singhal T, Davar N, Thakkar P. Initial Observations with Molecular Testing for COVID-19 in a Private Hospital in Mumbai, India. *Indian Journal of Pediatrics*. 2020; 87(7): 555.

20.	Ren LL, Wang YM, Wu ZQ, et al. Identification of a Novel Coronavirus Causing Severe Pneumonia in Human: a Descriptive Study. *Chinese Medical Journal*. 2020; 133(9): 1015-24.

21.	Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins.. *Annu Rev of Virology*. 2016; 3(1): 237—61.

22.	Susilo A, Rumende CM, Pitoyo CW, et al. Coronavirus Disease 2019: Tinjauan Literatur Terkini. *Jurnal Penyakit Dalam Indonesia*. 2020; 7(1): 45.

23.	Rothan HA, Byrareddy SN. Review Article The Epidemiology and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. *Journal of Autoimmunity*. 2020: 1-4.

24.	Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 Patophysiology: A Review. *Clinical Immunology*. 2020: 1-7.

25. Harrison AG, Lin T, Wang P. Review Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. *Trends in Immunology*, 2020; 41: 1100—15.

26. Sukmana M, Yuniarti FA. The Pathogenesis Characteristics and Symptom of Covid-19 in the Context of Establishing a Nursing Diagnosis. *Jurnal Kesehatatan Pasak Bumi Kalimantan*. 2020; 3(1): 21-28.

27. Fitriani NI. Tinjauan Pustaka COVID-19: Virologi, Patogenesis, dan Manifestasi Klinis. *Jurnal Medika Malahayati*. 2020; 4(3): 194—201.

28. Grace C. Manifestasi Klinis dan Perjalanan Penyakit pada Pasien COVID-19. *Majority*. 2020; 9: 49-55.

29. Alanagreh L, Alzoughool F, Atoum M. The Human Coronavirus Disease Covid-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. *Pathogens*. 2020; 9(5): 2-11.

30. Lin L, Lu L, Cao W, Li T. Hypothesis for Potential Pathogenesis of SARS-CoV-2 Infection–A Review of Immune Changes in Patients with Viral Pneumonia. *Emerging Microbes & Infections*. 2020; 9(1): 727-32.

31. Soeroto AY, Santoso P, Pranggono EH, et al. Review Article Khusus Kompendium Diagnostik dan Pengobatan Covid-19 (Interim) Perhimpunan Respirologi Indonesia (PERPARI). *Jurnal Penyakit Dalam Indonesia. Vol 7.* 2020; 7(1): 17-59.

32. Nagpal P, Narayanasamy S, Vidholia A, et al. Imaging of COVID-19 pneumonia: Patterns, pathogenesis, and advances. *British Journal of Radiology*. 2020; 93: 1-12.

33. Burhan E, Susanto AD, Nasution SA D. *Pedoman Tatalaksana COVID-19*. Ed II. Jakarta. 2020: 1—2.

34. Laksono SJ. Update WHO Recommendation on COVID-19 for Hospital. *Indonesia Country Office*. 2020: 1-34.

35. Widayat W, Winarni Agustini T, Suzery M, et al. Real Time-Polymerase Chain Reaction (RT-PCR) Sebagai Alat Deteksi DNA Babi dalam Beberapa Produk Non-Pangan. *Indonesian Journal of Halal*. 2019; 2(1): 26-33.

36. Handoyo D, Rudiretna A. Prinsip Umum dan Pelaksanaan Polymerase Chain Reaction (PCR). *Pusat Studi Bioteknologi-Universitas Surabaya*. 2001; 9(1): 17-28.

37. Hewajuli DA, Dharmayanti N. Perkembangan Teknologi Reverse Transcriptase-Polymerase Chain Reaction dalam Mengidentifikasi Genom Avian Influenza dan Newcastl. *Balai Besar Penelitian Veterine*. 2014: 24(1); 16—29.

38. Arya M, Shergill IS, Williamson M, et al. Basic Principles of Real-Time Quantitative PCR. *Expert Review of Molecular Diagnostics*. 2005; 5(2): 209-219.

39. Rahardianti R, Nur EM. Akurasi Metode Real PCR untuk Analisa Ekspresi Gen PmVRP15. Balai Besar Perikanan Budidaya Air Payau Jepara. 2017: 1-7.

40. Feranisa A. Komparasi Antara Polymerase Chain Reaction (PCR) dan Loopmediated Isothermal Amplification (LAMP) dalam Diagnosis Molekuler. *ODONTO Dental Journal*. 2016; 3(2): 145-51.

41. Agilent. Introduction to Quantitative PCR - Methods and Applications Guide. *Agilent Technology*. 2012: 1-42.

42. Kuntaman. Arti Klinis Nilai CT. *Perhimpunan Dokter Spesialis Mikrobiologi Klinik Indonesia*. 2020: 1-4.

43. Huang C, Wang Y, Li X, Ren L, Zhao J. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet*. 2020;395:497-506.

44. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Geneva. World Health Organization. 2020: 1-15.

45. Chen X, Zhao B, Qu Y, et al. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) is Closely Correlated with Drastically Elevated Interleukin 6 Level in Critically Ill Patients with Coronavirus Disease 2019. *International Journal of Infectious Diseases*. 2020; 71(8): 1937-42.

46. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *International Journal of Infectious Diseases*. 2020; 94: 154-5.

47. Zhang J, Wang X, Jia X, et al. Risk Factors for Disease Severity, Unimprovement, and Mortality in COVID-19 Patients in Wuhan, China. *Clinical Microbiology Infection*. 2020;:767-72.

48. Song CY, Xu J, He JQ, Lu YQ. COVID-19 Early Warning Score: A Multi-Parameter Screening Tool to Identify Highly Suspected Patients. *medRxiv*. 2020: 1-22.

49.   Karyono DR, Wicaksana AL. Current Prevalence, Characteristics, and Comorbidities of Patients with COVID-19 in Indonesia. *Journal of Community Empowerment for Health*. 2020; 3(2): 77-84.

50.   Goujon A, Natale F, Ghio D, et al. Age , Gender , and Territory of COVID-19 Infections and Fatalities. *Joint Research Centre*; 2020: 3-16.

51.   O'Brien J, Du KY, Peng C. Incidence, Clinical Features, and Outcomes of COVID-19 in Canada: Impact of Sex and Age. *Journal of Ovarian Research*. 2020; 13(1): 1-12.

52.   Jin JM, Bai P, He W, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front Public Health*. 2020: 1-6.

53.   Wenham C, Smith J, Morgan R. COVID-19: The Gendered Impacts of The Outbreak. *Lancet*. 2020; 395(10227): 846-8.

54.   Patel SK, Velkoska E, Burrell LM. Emerging Markers in Cardiovascular Disease: Where Does Angiotensin-Converting Enzyme 2 Fit in?. *Clinical & Experimental Pharmacology & Physiology*. 2013; 40(8): 551-9.

55.   Moran KR, Del Valle SY. A Meta-Analysis of the Association Between Gender and Protective Behaviors in Response to Respiratory Epidemics and Pandemics. *PLoS One*. 2016;11(10): 1-18.

56.   Chen N, Zhou M, Dong X, et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. *Lancet*. 2020; 395(10223):   507-13.

57.   Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *Journal of the American Medical Association*. 2020; 323(11): 1061-9.

58.   Guan W, Ni Z, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal Medicine*. 2020; 382(18): 1708-20.

59.   Pan F, Ye T, Sun P, Gui S, Liang B, Li L. Time Course of Lung Changes at Chest CT during Recovery. *Radiology*. 2020; 295(3): 715-21.

60.   Rao SN, Manissero D, Steele VR, et al. A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19. *Infectious Diseases and Therapy*. 2020; 9(3): 573-86.

61.   Zou L, Ruan F, Huang M, Lijun L. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal Medicine*. 2020; 382(12): 1175-7.

62. Pan Y, Zhang D, Yang P, et al. Viral Load of SARS-CoV-2 in Clinical Samples. *Lancet*. 2020; 20(4): 411-12.

63. Zhou R, Li F, Chen F, et al. Viral Dynamics in Asymptomatic Patients with COVID-19. *International Journal of Infectious Diseases*. 2020; 96: 288-90.

64. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal Profiles of Viral Load in Posterior Oropharyngeal Saliva Samples and Serum Antibody Responses During Infection by SARS-CoV-2: An Observational Cohort Study. *Lancet*. 2020; 20: 565-74.

65. Chu CM, Poon LLM, Cheng VCC, et al. Initial Viral Load and The Outcomes of SARS. *Canadian Medical Association Journal*. 2004; 171(11): 1349-52.

KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari.,MMed.PhD. SpGK. TELP. 081241850858. 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 775/UN4.6.4.5.31/ PP36/ 2020

Tanggal: 25 November 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20110659	No Sponsor Protokol	
Peneliti Utama	**dr. Wisnu Adryanto**	Sponsor	
Judul Peneliti	Hubungan Cycle Threshold (CT Values) SARS-CoV2 Pada Berbagai Derajat Keparahan Penyakit COVID-19		
No Versi Protokol	**1**	Tanggal Versi	17 November 2020
No Versi PSP		Tanggal Versi	
Tempat Penelitian	**RS Universitas Hasanuddin dan RSUP Dr. Wahidin Sudirohusodo Makassar**		

Jenis Review	[X] Exempted [ ] Expedited [ ] Fullboard Tanggal	Masa Berlaku 25 November 2020 sampai 25 November 2021	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan